Loading…
Stem cells-a hard sell to investors
A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.
Saved in:
| Published in: | Nature biotechnology 2005-07, Vol.23 (7), p.798-800 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c414t-208efe1b58bc780f41ef7c76309beabd73479977c980fcaab69f833e831efed43 |
|---|---|
| cites | |
| container_end_page | 800 |
| container_issue | 7 |
| container_start_page | 798 |
| container_title | Nature biotechnology |
| container_volume | 23 |
| creator | Giebel, Lutz B |
| description | A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists. |
| doi_str_mv | 10.1038/nbt0705-798 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68017158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1008623481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-208efe1b58bc780f41ef7c76309beabd73479977c980fcaab69f833e831efed43</originalsourceid><addsrcrecordid>eNptkc1Lw0AQxRdRbK2evEtU8KLR2WyyH0cpfkHBg3pedpOJtjRJ3U0K_vduSbAinmaG-fHe8IaQYwrXFJi8qW0LArJYKLlDxjRLeUy54ruhBylioBkfkQPvFwDAU873yYhyAMYyNSbnLy1WUY7LpY9N9GFcEfkwRG0Tzes1-rZx_pDslWbp8WioE_J2f_c6fYxnzw9P09tZnKc0beMEJJZIbSZtLiSUKcVS5IIzUBaNLQRLhVJC5Cosc2MsV6VkDCULIBYpm5CLXnflms8ueOtq7jenmRqbzmsugQqayQCe_QEXTefqcJtOkoRRqoLrhFz2UO4a7x2WeuXmlXFfmoLeBKeH4HQILtAng2RnKyy27JBUAK56wIdV_Y5u6_m_3mmP16btHP7o_XoW-wbS1YC1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222311976</pqid></control><display><type>article</type><title>Stem cells-a hard sell to investors</title><source>Nature</source><creator>Giebel, Lutz B</creator><creatorcontrib>Giebel, Lutz B</creatorcontrib><description>A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/nbt0705-798</identifier><identifier>PMID: 16003359</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Agriculture ; Bioinformatics ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biopsy ; Biotechnology ; Biotechnology - economics ; Biotechnology industry ; Bone marrow ; Cartilage ; commentary ; Ethics ; Humans ; Intellectual property ; Investments ; Life Sciences ; Market potential ; Neurodegenerative Diseases - therapy ; Product development ; Stem cell transplantation ; Stem Cell Transplantation - economics ; Stem Cell Transplantation - ethics ; Stem Cell Transplantation - legislation & jurisprudence ; Stem Cells ; Venture capital</subject><ispartof>Nature biotechnology, 2005-07, Vol.23 (7), p.798-800</ispartof><rights>Springer Nature Limited 2005</rights><rights>Copyright Nature Publishing Group Jul 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-208efe1b58bc780f41ef7c76309beabd73479977c980fcaab69f833e831efed43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2726,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16003359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giebel, Lutz B</creatorcontrib><title>Stem cells-a hard sell to investors</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.</description><subject>Agriculture</subject><subject>Bioinformatics</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Biotechnology</subject><subject>Biotechnology - economics</subject><subject>Biotechnology industry</subject><subject>Bone marrow</subject><subject>Cartilage</subject><subject>commentary</subject><subject>Ethics</subject><subject>Humans</subject><subject>Intellectual property</subject><subject>Investments</subject><subject>Life Sciences</subject><subject>Market potential</subject><subject>Neurodegenerative Diseases - therapy</subject><subject>Product development</subject><subject>Stem cell transplantation</subject><subject>Stem Cell Transplantation - economics</subject><subject>Stem Cell Transplantation - ethics</subject><subject>Stem Cell Transplantation - legislation & jurisprudence</subject><subject>Stem Cells</subject><subject>Venture capital</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNptkc1Lw0AQxRdRbK2evEtU8KLR2WyyH0cpfkHBg3pedpOJtjRJ3U0K_vduSbAinmaG-fHe8IaQYwrXFJi8qW0LArJYKLlDxjRLeUy54ruhBylioBkfkQPvFwDAU873yYhyAMYyNSbnLy1WUY7LpY9N9GFcEfkwRG0Tzes1-rZx_pDslWbp8WioE_J2f_c6fYxnzw9P09tZnKc0beMEJJZIbSZtLiSUKcVS5IIzUBaNLQRLhVJC5Cosc2MsV6VkDCULIBYpm5CLXnflms8ueOtq7jenmRqbzmsugQqayQCe_QEXTefqcJtOkoRRqoLrhFz2UO4a7x2WeuXmlXFfmoLeBKeH4HQILtAng2RnKyy27JBUAK56wIdV_Y5u6_m_3mmP16btHP7o_XoW-wbS1YC1</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Giebel, Lutz B</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Stem cells-a hard sell to investors</title><author>Giebel, Lutz B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-208efe1b58bc780f41ef7c76309beabd73479977c980fcaab69f833e831efed43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Agriculture</topic><topic>Bioinformatics</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Biotechnology</topic><topic>Biotechnology - economics</topic><topic>Biotechnology industry</topic><topic>Bone marrow</topic><topic>Cartilage</topic><topic>commentary</topic><topic>Ethics</topic><topic>Humans</topic><topic>Intellectual property</topic><topic>Investments</topic><topic>Life Sciences</topic><topic>Market potential</topic><topic>Neurodegenerative Diseases - therapy</topic><topic>Product development</topic><topic>Stem cell transplantation</topic><topic>Stem Cell Transplantation - economics</topic><topic>Stem Cell Transplantation - ethics</topic><topic>Stem Cell Transplantation - legislation & jurisprudence</topic><topic>Stem Cells</topic><topic>Venture capital</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giebel, Lutz B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giebel, Lutz B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stem cells-a hard sell to investors</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>23</volume><issue>7</issue><spage>798</spage><epage>800</epage><pages>798-800</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16003359</pmid><doi>10.1038/nbt0705-798</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2005-07, Vol.23 (7), p.798-800 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68017158 |
| source | Nature |
| subjects | Agriculture Bioinformatics Biomedical Engineering/Biotechnology Biomedicine Biopsy Biotechnology Biotechnology - economics Biotechnology industry Bone marrow Cartilage commentary Ethics Humans Intellectual property Investments Life Sciences Market potential Neurodegenerative Diseases - therapy Product development Stem cell transplantation Stem Cell Transplantation - economics Stem Cell Transplantation - ethics Stem Cell Transplantation - legislation & jurisprudence Stem Cells Venture capital |
| title | Stem cells-a hard sell to investors |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A44%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stem%20cells-a%20hard%20sell%20to%20investors&rft.jtitle=Nature%20biotechnology&rft.au=Giebel,%20Lutz%20B&rft.date=2005-07-01&rft.volume=23&rft.issue=7&rft.spage=798&rft.epage=800&rft.pages=798-800&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/nbt0705-798&rft_dat=%3Cproquest_cross%3E1008623481%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-208efe1b58bc780f41ef7c76309beabd73479977c980fcaab69f833e831efed43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222311976&rft_id=info:pmid/16003359&rfr_iscdi=true |